Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S332000, C514S336000, C546S280400, C546S283400, C546S318000, C546S322000
Reexamination Certificate
active
06995179
ABSTRACT:
Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc.
REFERENCES:
patent: 6350766 (2002-02-01), Uneyama et al.
patent: 2 407 115 (1974-10-01), None
patent: 26 58 804 (1978-07-01), None
patent: 0 110 073 (1984-06-01), None
patent: 0 173 943 (1986-03-01), None
patent: 0 315 018 (1989-05-01), None
patent: 0 622 368 (1994-11-01), None
patent: 0 657 429 (1995-06-01), None
patent: 0 779 277 (1997-06-01), None
patent: 60-233058 (1985-11-01), None
patent: 61-068488 (1986-03-01), None
patent: 61-68488 (1986-04-01), None
patent: 63-258874 (1988-10-01), None
patent: 64-75467 (1989-03-01), None
patent: 2-121967 (1990-05-01), None
patent: 3-240773 (1991-10-01), None
patent: WO 93/13128 (1993-07-01), None
Iqbal, Nadeem, et al. “Synthesis, Rotamer Orientation, and Ca. Channel Modulation Activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3-or 6-subst.-2-pyridyl)-5-pyridinecarboxylates” J. of Med. Chem. (1998), 41(11), pp. 1827-1837.
Iqbal et al “Synthesis, Rotamer Orientation, and Ca. Channel Modulation Activities of alkyl and 2-phenylethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6- subst. 2-pyridyl)-5-pyridinecarboxylates” J. of Med. Chem. (1998), 41(11), pp. 1827-1837.
Iqbal, Nadeem, et al. “Synthesis, Rotamer Orientation, and Ca. Channel Modulation Activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-subst.-2-pyridyl)-5-pyridinecarboxylates” J. of Med. Chem. (1998), 41(11), pp. 1827-1837.
Masahiro Hosono et al.,Inhibitory Effect of Cilnidipine on Vasocular Sympathetic Neurotransmission and Subsequent Vasoconstriction in Spontaneously Hypertensive Rats, Jpn. J. Pharmacol., vol. 69, pp. 127-134, 1995.
Shigeo Fujii et al.,Effect of Cilnidipine, a Novel Dihydropyridine Ca ++ -Channel Antagonist, on N-Type Ca++ Channel in Rat Dorsal Root Ganglion Neurons, The Journal of Pharmacology and Experimental Therapeutics, vol. 280, N. 4, pp. 1184-1191, 1997.
Natsuki Nakayama et al.,Antihypertensive Activity of OPC-13340, a New Potent and Long-Acting Dihydropyridine Calcium Antagonist, in Rats, Journal of Cardiovascular Pharmacology, vol. 15, pp. 836-844, 1990.
Virginia D. Monje et al.,A New Conus Peptide Ligand for Ca Channel Subtypes, Neuropharmacology, vol. 32, No. 11, pp. 1141-1149, 1993.
Hisayuki Uneyama et al.,Blockage of N-Type Ca2+Current by Cilnidipine(FRC-8653)in Acutely Dissociated Rat Sympathetic Neurones, British Journal of Pharmacology, vol. 122, pp. 37-42, 1997.
Niwa Seiji
Onishi Tomoyuki
Uneyama Hisayuki
Ajinomoto Co. Inc.
Coppins Janet L.
McKane Joseph K.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Dihydropyridine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyridine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyridine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3686060